Market Overview

UPDATE: Oppenheimer Downgrades ImmunoGen to Perform on Valuation

Share:
Related IMGN
Biotech Investors: May 29th Could Be A Big Day
5 Biotech Earnings Under The Microscope This Week

Oppenheimer downgraded ImmunoGen (NASDAQ: IMGN) from Outperform to Perform and maintained a $14.00 price target.

Oppenheimer noted, "We are downgrading IMGN to Perform from Outperform and maintaining our $14 price target, as we believe the success of T-DM1 is now fully priced into the stock. We are warming to IMGN901 and will watch the NORTH study as it will likely be the next driver of IMGN that could move us off the sidelines. A NORTH update is expected 2H13. With the launch of T-DM1, as with any drug launch, initial Street expectations may be adjusted. A post-launch pullback in IMGN into low teens may also cause us to revisit our rating."

ImmunoGen closed at $15.04 on Friday.

Latest Ratings for IMGN

DateFirmActionFromTo
May 2015Credit SuisseAssumesNeutral
Mar 2015Cantor FitzgeraldUpgradesHoldBuy
Feb 2015OppenheimerUpgradesMarket PerformOutperform

View More Analyst Ratings for IMGN
View the Latest Analyst Ratings

Posted-In: OppenheimerAnalyst Color Downgrades Pre-Market Outlook Analyst Ratings

 

Related Articles (IMGN)

Around the Web, We're Loving...

Get Benzinga's Newsletters